An observational study in Age-Related Macular Degeneration and Geographic Atrophy, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of California, San Francisco · Observational
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's planned enrollment of 80 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with age-related macular degeneration.
Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.
Exclusion Criteria:
Subjects with a baseline size of GA > 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).
Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.
Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):
Patients with age-related macular degeneration who have geographic atrophy that does not involve the fovea.
Diagnostic Test: Optical coherence tomography · Diagnostic Test: Microperimetry
Patients with intermediate age-related macular degeneration
Diagnostic Test: Optical coherence tomography · Diagnostic Test: Microperimetry
Patients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition.
Diagnostic Test: Optical coherence tomography · Diagnostic Test: Microperimetry
Patients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition.
Diagnostic Test: Optical coherence tomography · Diagnostic Test: Microperimetry
High-resolution imaging method used to evaluate the structure of the retina
Also known as: OCT
A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.
Geographic atrophy progression rate
Quantify the progression rate of geographic atrophy toward the foveal center over time
Time frame: 1 year
Longitudinal progression of macular sensitivity over time
Measure macular sensitivity over time.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco